Nonalcoholic Steatohepatitis Nash clinical trials

Explore recruiting nonalcoholic steatohepatitis nash clinical trials.

Recruiting nonalcoholic steatohepatitis nash studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nonalcoholic Steatohepatitis Nash trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

Spain, Belgium, Austria, Czechia, Portugal, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

France, Italy, Germany, Spain, Poland, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis

Spain, Germany, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

Spain, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicentre, randomised, double-blind, placebo-controlled, 48-week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed nonalcoholic steatohepatitis (NASH)

Germany, Spain, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Bulgaria, Germany, Spain, Poland, Portugal, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Nonalcoholic Steatohepatitis Nash trials by city

Nonalcoholic Steatohepatitis Nash clinical trials

Recruiting nonalcoholic steatohepatitis nash studies right now

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Effect of a GnRH Analog on Hepatic Steatosis

Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

Also recruiting in Europe

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

Multicentre, randomised, double-blind, placebo-controlled, 48-week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed nonalcoholic steatohepatitis (NASH)

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patient with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Nonalcoholic Steatohepatitis Nash trials by city

Other conditions